ArticleEye (London, England)2025
Management and outcomes of ocular surface squamous neoplasia at a tertiary hospital, South Africa.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Management and outcomes of ocular surface squamous neoplasia at a tertiary hospital, South Africa.Eye (London, England) · 2026Article
- Comment on "Management and outcomes of ocular surface squamous neoplasia" by Höllhumer et al. (Eye, 2025).Eye (London, England) · 2026Article
- Case Report: Successful control of ocular surface squamous neoplasia complicated byFrontiers in medicine · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of this study is to describe the outcomes of OSSN management at a tertiary eye hospital in Johannesburg, South Africa.
methodsThis was a prospective interventional study, which included patients presenting with conjunctival masses at a tertiary eye hospital from December 2019 to February 2022. An electronic questionnaire was completed to document demographic data, presenting history, and associated risk factors. All patients had a biopsy to confirm the diagnosis. Tumours that occupied less than or equal to 4 limbal clock hours had an excision biopsy. Larger tumours had an incision biopsy followed by topical 5-fluorouracil (5FU) as primary management. Recurrences and positive margins were managed with 5FU. Patients were followed up for 2 years to monitor for recurrence.
resultsOne hundred and nine patients with 114 conjunctival masses were included in this study. Ninety-four percent (107/114) of patients had an excision biopsy as their primary management, with a recurrence rate of 0.9% (1/107). Seven patients had 5FU as primary therapy with a complete resolution rate of 71% (5/7) and a recurrence rate of 14% (1/7).
conclusionA standardised management approach for OSSN based on the size of the tumour resulted in high resolution rates and a low rate of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.